Inhaled Nitric Oxide Market

Market Overview The Global Inhaled Nitric Oxide Market is projected to expand significantly, rising from USD 789.21 Million in 2025 to USD 1199.75 Million by 2031, demonstrating a compound annual growth rate of 7.23%. This specialized gaseous blend, administered via inhalation, acts as a selective pulmonary vasodilator, primarily prescribed for term and near-term neonates experiencing hypoxic respiratory failure linked to pulmonary hypertension. The market's growth is fundamentally propelled by the increasing incidence of neonatal respiratory conditions and the crucial demand for effective, non-invasive therapeutic solutions within neonatal intensive care units worldwide, consistently driving the need for pharmaceutical-grade gas and compatible delivery systems. However, despite these strong drivers, the market faces significant challenges due to the high cost of therapy and stringent reimbursement policies, which can restrict widespread adoption, particularly in healthcare settings with budget limitations. This ongoing clinical necessity is further underscored by recent health statistics, such as the March of Dimes report from 2024, indicating that the preterm birth rate in the United States remained historically high at 10.4 percent, thereby emphasizing the continuous requirement for advanced neonatal respiratory care. Market Driver A primary catalyst for the inhaled nitric oxide market's expansion is the rising global prevalence of preterm births and subsequent neonatal intensive care admissions. Premature infants frequently suffer from underdeveloped lungs and conditions such as Persistent Pulmonary Hypertension of the Newborn (PPHN), which necessitate immediate vasodilatory support. This demographic trend ensures a steady patient pool for nitric oxide therapies, which are recognized as the standard of care for hypoxic respiratory failure in term and near-term neonates. The Centers for Disease Control and Prevention's 'Births: Provisional Data for 2024' report, released in April 2025, confirmed a U.S. preterm birth rate of 10.41 percent, while Mallinckrodt plc reported net sales of $60.8 million for its INOmax franchise in the fourth quarter of 2024 alone, highlighting sustained commercial demand. Concurrently, technological advancements in portable and precision nitric oxide delivery systems are transforming the competitive landscape by overcoming the logistical constraints associated with traditional gas cylinders. Innovative tankless devices that generate nitric oxide from ambient air are gaining significant traction, enabling easier transport and broader adoption beyond conventional intensive care settings. These innovations streamline hospital operations and simplify supply chains, accelerating the uptake of next-generation solutions. For example, Beyond Air, Inc.'s 'Fourth Quarter and Full Year 2025 Financial Results' from June 2025 revealed a 220 percent year-over-year increase in revenue for its tankless LungFit PH system, reaching $3.7 million. These advancements expand the addressable market by allowing therapy administration during patient transport and in lower-acuity wards where heavy cylinders were previously impractical. Market Challenge The substantial cost of inhaled nitric oxide therapy, coupled with restrictive reimbursement policies, presents a significant impediment to the global market's growth. Healthcare institutions, particularly those operating under tight budgets, often struggle to justify the considerable expenses associated with acquiring pharmaceutical-grade gas and specialized delivery systems. This financial pressure typically leads hospitals to reserve inhaled nitric oxide for only the most severe cases, thereby hindering its broader adoption across various neonatal intensive care units and limiting market penetration in price-sensitive regions where more affordable treatments are often prioritized. The economic burden of this therapy is particularly impactful when considering the duration of a standard treatment course; for instance, the National Institutes of Health estimated the cost of inhaled nitric oxide therapy at approximately $220 per hour in 2024. Such high operational expenses complicate the reimbursement environment, prompting insurance providers to enforce rigorous inclusion criteria to control healthcare spending. These stringent policies frequently result in claim denials or limited coverage, which in turn discourages healthcare facilities from routinely stocking or administering the therapy, directly impeding overall market expansion. Market Trends A notable market trend involves a growing focus on non-invasive delivery methods for chronic respiratory conditions, extending therapeutic applications beyond traditional neonatal intensive care units. Industry players are increasingly investing in the development of lightweight, ambulatory devices capable of generating nitric oxide on-demand, which facilitates the long-term management of adult indications such as pulmonary hypertension associated with interstitial lung disease in home-care settings. This strategic shift towards addressing chronic patient populations is backed by substantial capital inflows aimed at commercializing next-generation technologies, as exemplified by Third Pole Therapeutics, which secured a $16.9 million funding round in March 2025 to accelerate the development and deployment of its portable, cylinder-free nitric oxide platform for these expanded care environments. Simultaneously, there is a significant acceleration in strategic alliances designed to create integrated respiratory care solutions, aimed at facilitating global market penetration and optimizing therapy delivery. Manufacturers are progressively moving away from solely relying on direct sales models in international territories, instead choosing to forge partnership agreements with regional distributors. This strategy helps navigate complex regulatory frameworks and allows for the bundling of nitric oxide therapies with complementary respiratory products. This expansion approach is evidenced by recent commercial developments, such as Beyond Air, Inc.'s December 2025 press release, which highlighted the company's successful expansion of its global commercial footprint to 39 countries through new distribution contracts for key markets including Germany and Brazil. Key Market Players * Linde PLC * Air Liquide Healthcare * BOC Healthcare * Matheson Tri-Gas Inc. * Merck KGaA * Nu-Med Plus Inc. * Perma Pure LLC * Praxair Distribution Inc. * HALMA PLC Report Scope In this report, the Global Inhaled Nitric Oxide Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Inhaled Nitric Oxide Market, By Product Type * Gas * Delivery Systems # Inhaled Nitric Oxide Market, By Application * Neonatal Respiratory Treatment * Asthma and COPD * Acute Respiratory Distress Syndrome * Malaria Treatment * Tuberculosis Treatment * Other Applications # Inhaled Nitric Oxide Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Inhaled Nitric Oxide Market. Available Customizations: Global Inhaled Nitric Oxide Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).